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Editorial
Pancreatic transplantation for patients with Type I
diabetes
Diabetes mellitus is the principal cause of kidney failure and
blindness in adults and leads to more cases of amputations
and impotence than any other disease. It is one of the most
common chronic diseases of childhood. In the USA diabetes
costs $138 billion each year; that is one out of every $7 spent
on health care. The aim of pancreas transplantation is to
improve quality of life of patients with Type I insulin-
dependent diabetes mellitus (IDDM) and to ameliorate
secondary complications by establishing an insulin-
independent euglycaemic state. This aim is achieved by
engrafting insulin-producing b cells in the islets of
Langerhans.
IDDM includes not only abnormal glucose metabolism
but also specific microvascular complications such as
retinopathy, nephropathy and neuropathy. Over the last
15 years, it has become increasingly evident that the
microvascular complications of diabetes mellitus result from
hyperglycaemia. Exogenous insulin therapy prevents acute
metabolic decompensation and, when delivered so as to
achieve near-normal glucose concentrations, reduces the
frequency of many complications. Even in well-controlled
patients, exogenous insulin administration does not achieve
the level of control effected by endogenous insulin secretion,
which responds to moment-by-moment changes in glucose
concentration. Pancreas transplantation is the only treat-
ment for IDDM that is able to induce insulin independence
consistently and that normalises glucosylated haemoglobin.
Patients who can be considered for a pancreas
transplant fall into three categories:
(i) Those who have had a previous kidney transplant
and are already on anti-rejection drugs: pancreas after
kidney (PAK).
(ii) Those who have failed or failing kidneys and need a
kidney transplant. Such patients are on dialysis, or
will soon need dialysis unless a kidney transplant is
done first. In such patients, a kidney and pancreas
can be transplanted simultaneously from a cadaver
donor: simultaneous pancreas and kidney (SPK). 
(iii) Those who need only a pancreas transplant, pancreas
transplant alone (PTA). An individual whose kid-
neys have not failed can receive a pancreas transplant
alone. Diabetic complications such as neuropathy
must be present, or there must be extreme difficulty
with diabetic control. This restriction is imposed
because of the need for immunosuppressive drugs to
prevent rejection.
Patient selection is aided by a comprehensive multidis-
ciplinary pretransplant evaluation, with additional work-up
according to the specific problems of each patient. Renal
dysfunction with a creatinine clearance <20 ml/minute is
used to select patients for simultaneous pancreas–kidney
transplantation versus pancreas transplantation alone
(creatinine clearance >70 ml/minute). If the creatinine
clearance is 40–70 ml/minute the patient can be offered a
pre-emptive kidney transplant.
The immunosuppression for pancreas transplantation is
similar to that for other solid organs. The idea is to max-
imise the immunosuppressive effects and minimise immun-
odeficient complications and toxicity by using multiple
agents at low doses. Since the mid-1980s, almost every pro-
gramme has used cyclosporin in combination with
azathioprine and prednisone for maintenance immuno-
suppression; most (>85%) also use anti-T cell agents for
induction, although there is a recent change in practice
to no induction at all. Lately, several institutions have
achieved promising results using tracrolimus instead of
cyclosporin for maintenance therapy. It is currently the pri-
mary immunosuppressant in 20% of pancreas transplants.
Azathioprine is being replaced by mycophenolate mofetil
(MMF).
Although transplantation requires a life-long commit-
ment to immunosuppression, most diabetic patients find
that they have fewer dietary and activity restrictions and a
much better quality of life after pancreas transplantation.
There is no evidence that immunosuppressive drugs are
associated with any more complications than diabetes over
a 20-year period. Early pancreas transplantation can pre-
vent secondary complications and, even when done late, it
has been shown to improve nerve damage caused by dia-
betes. It would be reasonable for a person with diabetes to
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choose to have a pancreas transplant with long-term
immunosuppression rather than a lifetime with diabetes.
From 1966 to date over 15,000 pancreas transplanta-
tions have been performed world-wide, most in the last 10
years. According to the United Network for Organ Sharing
(UNOS) Register [1] established in 1987:
n 84% of pancreas transplantations were preformed in
conjunction with a kidney transplantation in
patients who had imminent renal failure or were on
dialysis.
n 8% were performed as a sequential pancreas-after-
kidney transplantation.
n 6% were preformed as a solitary transplantation.
n 2% were preformed in conjunction with a single
organ transplantation other than the kidney or with
multiple organs.
The results of pancreas transplantation have improved
progressively since the introduction of cyclosporin and,
more recently, tacrolimus, plus the refinement of surgical
techniques [2,3]. In an analysis of 4500 cadaver donor cases
reported world-wide between 1987 and 1996 [1], the overall
one-year patient survival rate was 92% and the one-year
insulin-dependent rate was 79%[1]. One-year kidney graft
survival rate was 70% in Europe, 78% in the USA and 75%
in the rest of the world. In the last decade operative mor-
tality has been 1 to 3 % in most established centres. At
St Mary’s Hospital, London we have introduced a new tech-
nique of whole organ kidney pancreas transplant with syn-
chronous implantation of the two grafts, with an operative
time of 120 6 15 minutes, 100% patient and graft survival
and minimal blood transfusion [4]. This experience should
encourage many more centres to start this type of transplant.
In addition to correcting dysmetabolism and freeing the
patient from exogenous insulin therapy, there is evidence
that pancreas transplantation has a beneficial effect on the
course of secondary diabetic complications. In some studies
with follow-up of four years or more after successful pan-
creas transplantation, stabilisation of retinopathy was bet-
ter then that observed in patients followed for the same
period of time but whose pancreas transplants had failed.
Both prospective and cross-sectional studies have sug-
gested that pancreas transplantation prevents recurrence of
diabetic nephropathy in a newly transplanted kidney. Stud-
ies have reported improved motor and sensory nerve func-
tion as assessed by nerve conduction velocity in
pancreas–kidney transplant recipients, when compared to
recipients of kidney transplants alone or patients with pan-
creas graft failure. Studies of autonomic function following
pancreas transplantation are less clear. In some studies,
pancreas transplantation was associated with greater
improvement in autonomic symptoms, even it they were
accompanied by little objective evidence of change.
The improvement in success rates has led to increasing
interest in PTA in non-uraemic patients. More than 850
PTAs have been carried out so far world-wide. As recently
as 1996 there was a big difference in the one-year graft sur-
vival between SPK (79%), PAK (60%) and PTA (57%),
the main reason being the high incidence of rejection.
Indeed, the incidence of late acute rejection was 7% in
SPK, 25% in PAK and 41% in PTA.
Studies are unanimous in finding that patients with
successful transplants rate their lives better after transplan-
tation than before. The effect of a double transplant in
uraemic diabetic patients can be dramatic; patients rate
their quality of life higher than diabetics who receive a
kidney transplant alone.
The advances in immunosuppressive strategies and
diagnostic technology will improve the good results
achieved with pancreas transplantation so far. Further
documentation of the long-term benefits and effects of
pancreas transplantation may lead to wider availability and
acceptance. Effective control of rejection with earlier diag-
nosis or better prevention may soon permit solitary
pancreas transplantation to become an accepted treatment
option in diabetic patients without advanced secondary
complications of diabetes. Although there is an appreciable
morbidity rate after pancreas transplantation, complica-
tions can usually be managed without adversely influencing
the outcome. Other strategies for the treatment of IDDM
are being actively investigated, including islet cell and fetal
pancreas transplants, xenogenetic islet gene therapy,
implantable insulin pumps and bio-hybrid artificial
pancreas units.
With regard to islet transplantation, since 1989 several
groups have succeeded in establishing insulin independ-
ence in occasional diabetic recipients by intraportal islet
transplantation. Consistent islet allograft success has
recently been achieved by using multiple donors and a
steroid-free immunosuppression regimen at the University
of Alberta in Edmonton. Thus, engrafting an adequate b
cell mass appears to be the critical factor for clinical islet
transplant to succeed. The challenge now is to achieve
consistent success with a single donor. That this goal
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should be possible is apparent from the fact that islet auto
transplantation after total pancreatectomy can sustain
insulin independence, as shown by the very first case in the
late 1970s.
Perhaps there will be a role for both islet and pancreas
transplantation , with islet transplantation reserved for dia-
betic individuals with a low insulin requirement, while
pancreas transplant may be preferable for those with a high
insulin requirement or insulin resistance, such as those with
Type II diabetes. Pancreas transplantation will also be pre-
ferred in individuals who are diabetic as a result of total
pancreatectomy, in whom enteric drainage could be used to
correct exocrine deficiency, as was first done in the 1980s.
Indeed, if an unlimited supply of b cells for transplantation
could be obtained (xenografts of human cell lines), the
future of pancreas transplantation could primarily be to
correct exocrine deficiency, for which the groundwork has
already been laid [5].
Although any or all of these methods may have a role
in the treatment of IDDM in the future, it will be difficult
for these alternative strategies to improve on the metabolic
efficiency of the vascularised pancreas transplant. With the
improvement in quality of life and the potential reversing
effect on diabetic complications, pancreas transplantation
may become a more common transplant procedure and may
soon become the treatment of choice for IDDM.
Nadey S Hakim
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